This phase II trial studies the use of an automated text-messaging program in improving medication adherence in patients taking oral medications for lung cancer. An automated text messaging program may help patients with lung cancer improve medication adherence and symptom management, improve monitoring of self-based care and decrease unplanned care.
Additional locations may be listed on ClinicalTrials.gov for NCT04347161.
See trial information on ClinicalTrials.gov for a list of participating sites.
PRIMARY OBJECTIVES:
I. To evaluate the effect of a mobile phone-based intervention (“Penny”), compared to usual care, on patient adherence to oral targeted therapies using a two-arm randomized-controlled trial.
II. To use mixed methods approaches with clinicians and patients to explore factors shaping the acceptability, effectiveness, and future implementation of Penny into routine cancer care.
EXPLORATORY OBJECTIVES:
I. Explore the impact of the intervention on patient-reported outcomes including patient satisfaction, medication self-efficacy, and other outcomes.
II. Explore if symptom management or self-efficacy mediates the relationship between arm assignment and adherence.
III. Explore any potential effect modification across different patient subgroups based on patient demographics, health literacy, social determinants of health, clinical characteristics, and other factors.
OUTLINE: Patients are randomized to 1 of 2 arms.
ARM I: Patients use Penny for 12 weeks, which includes text message reminders daily to take cancer medication and asking about any symptoms. Patients may participate in an interview.
ARM II: Patients receive usual care for symptom monitoring and management of side effects.
Trial PhasePhase II
Trial Typesupportive care
Lead OrganizationUniversity of Pennsylvania/Abramson Cancer Center
Principal InvestigatorKatharine Rendle
